00867 China Medical System Holdings Ltd.

NOTICE TO DISREGARD -- China Medical System Holdings Ltd.

NOTICE TO DISREGARD -- China Medical System Holdings Ltd.

SHENZHEN, CHINA, Dec. 21, 2022 (GLOBE NEWSWIRE) -- We are advised by China Medical System Holdings Ltd. that journalists and other readers should disregard the news release, "CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient" issued December 6, 2022, over GlobeNewswire.



EN
21/12/2022

Underlying

00867China Medical System Holdings Ltd.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on China Medical System Holdings Ltd.

 PRESS RELEASE
Free
00867 China Medical S...

CMS(867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received...

CMS(867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity SHENZHEN, CHINA, March 05, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals. About...

March 5, 2026 1 EN
 PRESS RELEASE
Free
00867 China Medical S...

CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (...

CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China SHENZHEN, CHINA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for deta...

February 24, 2026 1 EN
 PRESS RELEASE
Free
00867 China Medical S...

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Ap...

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China SHENZHEN, CHINA, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) recei...

January 30, 2026 1 EN
 PRESS RELEASE
Free
00867 China Medical S...

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib ...

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China SHENZHEN, CHINA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has...

December 15, 2025 1 EN
 PRESS RELEASE
Free
00867 China Medical S...

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Isch...

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China SHENZHEN, CHINA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the ...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch